# Novanta Inc. account plan

> Novanta supplies components and sub-systems to medical, life science and advanced industrial OEMs, with FY2025 revenue of $980.6 million.

## At a glance

Novanta Inc., founded in 1968 as General Scanning and organised as a holding company in Canada, engineers components and sub-systems that medical, life science and advanced industrial OEMs build into their own systems, sold mostly through a direct technical sales force. FY2025 revenue was $980.6 million (+3.3%), with operating income of $94.0 million and net income of $53.8 million; the medical market was approximately 53% of revenue and the United States 52.9%. It had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia. Customer concentration is high: the top ten customers made up approximately 42% of 2025 sales. The July 2026 acquisition of Riverpoint Medical, the largest in its history, raises its medical share further.

## Business units

- **Robotics and Automation (Automation Enabling Technologies)** (about 32% of FY2025 revenue ($318.6 million)): Precision motion, servo drives, force torque and position sensors, robotic end-of-arm tooling and air bearing spindles for industrial, medical, warehouse and humanoid robots and semiconductor work. Revenue rose $30.3 million in 2025 and 17.3% in Q3 2026; air bearing spindles are sold out for two years.
- **Precision Manufacturing (Automation Enabling Technologies)** (about 19% of FY2025 revenue ($182.3 million)): Laser beam steering and scanning solutions and laser sources for additive manufacturing, laser marking, micromachining, metrology and PCB and semiconductor manufacturing. Revenue declined $20.0 million in 2025 but grew 13.7% in Q3 2026. AET is led by Co-COO Chuck Ravetto.
- **Advanced Surgery (Medical Solutions)** (about 25% of FY2025 revenue ($242.4 million)): Insufflators, endoscopic pumps, fluid management and related consumables for minimally invasive surgery, now including Riverpoint Medical's sutures and implantable materials. Revenue rose $33.7 million in 2025 and the unit grew 12% organically in Q3 2026. Medical Solutions is led by Co-COO John Lesica.
- **Precision Medicine (Medical Solutions)** (about 24% of FY2025 revenue ($237.3 million)): Imaging, identification and RFID solutions (including Keonn), motion control subsystems for life science and medical equipment, optical light engines and operating room video technologies. Revenue fell $12.6 million in 2025 and 5% in Q3 2026 after a decision not to pursue lower-margin business.

## Strategic priorities

- **More medical, more recurring**: Management steers toward medical end markets, now 53% of revenue and approaching 60% on a full-year basis with Riverpoint, and recurring consumables, roughly 25% of revenue.
- **Organic growth through new products**: Long-term algorithm of mid to high single-digit organic growth; new product revenue rose 23% in Q3 2026 and advanced surgery targets approximately $400 million in revenue by 2030.
- **Deleveraging after Riverpoint**: The near-term capital deployment priority is to delever; net leverage stood at 2.2 at the end of Q3 2026.
- **Regional manufacturing footprint**: Regionalize manufacturing into centers of excellence and go from 21 to 18 factories by end of Q1 2027, under a restructuring program costing about $25.0 million in total by end-2026.
- **Physical AI and robotics**: Grow in robotics, which management describes as a roughly $2 billion addressable market growing about 10% a year, including warehouse automation and humanoids.

## Latest results

In Q3 2026 (quarter ended 2 October 2026) revenue rose 23.1% to $305.0 million, with Riverpoint Medical adding $32.9 million and organic growth of nearly 10%. Automation Enabling Technologies grew 16.0% to $145.4 million with a 50.2% gross margin, while Medical Solutions grew 30.3% to $159.7 million but its gross margin fell to 39.9%. Operating income fell 36.3% to $13.9 million on acquisition, restructuring and amortization costs, while adjusted EBITDA rose 38% to $80 million. Backlog was $543 million. Full-year 2026 guidance is revenue of $1,135-1,140 million, adjusted EBITDA of $274-277 million and operating cash flow of about $200 million, with a production slowdown at the Stockport (U.K.) factory weighing on Q4 margins.

## Investments and deals

- **Riverpoint Medical**: Minimally invasive surgical consumables maker acquired on 23 July 2026 for $1,200.6 million upfront net of cash, plus a $250.0 million milestone payable by 8 January 2027.
- **Keonn Technologies**: Barcelona RFID specialist acquired on 8 April 2025 for EUR 64.8 million ($71.0 million) net of cash, with up to EUR 20.0 million contingent consideration.
- **Acquisition funding**: $613.1 million net from 6.50% tangible equity units in November 2025, a $300 million private placement at $140.00 per share in June 2026, and a $200.0 million delayed draw term loan.
- **New financial and operations system**: A new ERP system is being implemented, with SAP MRP live at two lighthouse sites; it was a cost driver in 2025.
- **China spindle capacity**: A customer-co-funded China expansion for air bearing spindles should be fully ramped by April 2027.

## Challenges and risks

- **Customer concentration**: Two medical OEMs represented approximately 12% and 11% of 2025 revenue and the top ten customers approximately 42%.
- **Factory transfers and margins**: Regional manufacturing transfers created dual running costs; the Stockport production slowdown is roughly a 200 basis point gross margin headwind in Q4 2026.
- **Component and rare-earth supply**: Shortages of components from AI-related demand, Chinese export licences on rare-earth materials and magnets, tariffs, and higher energy and freight costs from the 2026 Iran conflict.
- **Higher leverage**: Riverpoint was funded with $616.0 million of revolver and delayed draw borrowings, taking leverage to 2.43 against a 4.00 covenant.
- **Precision medicine softness**: Precision medicine sales fell 5% in Q3 2026 and life science volume is lower; a return to growth is expected in late 2027.

## What leadership says

> "more medical, more recurring, and less cyclical" — Matthijs Glastra, Chair and CEO, Q3 2026 earnings call, November 10, 2026

> "Our near-term capital deployment priority is to delever" — Matthijs Glastra, Chair and CEO, Q3 2026 earnings call, November 10, 2026

> "A design win in one business becomes the invitation into the next." — Matthijs Glastra, Chair and CEO, Q3 2026 earnings call, November 10, 2026

> "Operating in region for region with a supply base close to our factories and our customers is proving to be a real advantage." — Robert Buckley, CFO, Q3 2026 earnings call, November 10, 2026


## Where a supplier can help

- **Regional supply base**: The regional manufacturing footprint and tight rare-earth and electronic component supply create demand for in-region suppliers of magnets, electronic components and materials close to Novanta factories.
- **Factory consolidation support**: Closing factories down to 18 and the Stockport slowdown point to needs in manufacturing transfer, quality testing and production engineering services.
- **ERP and operations systems**: The ongoing financial and operations system implementation, with SAP MRP at lighthouse sites, opens room for ERP integrators and supply-chain planning tools.
- **Riverpoint integration**: Integrating the largest acquisition in its history while deleveraging favours integration, procurement savings and medical consumables manufacturing partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Novanta Inc. Form 10-K for fiscal year 2025 (year ended December 31, 2025)](https://www.sec.gov/Archives/edgar/data/1076930/000119312526064230/novt-20251231.htm)

Annual report · 2026-02-23

- Novanta Inc. is a global supplier of core technology solutions (components and sub-systems) to medical, life science and advanced industrial OEMs; founded in 1968 as General Scanning, renamed Novanta in May 2016 and organised as a holding company in Canada.
- FY2025 revenue was $980.6 million (+3.3%), of which the 2025 acquisition (Keonn) added $21.8 million and FX $14.6 million; operating income fell 15.0% to $94.0 million and diluted EPS to $1.47 from $1.77.
- Two reportable segments: Automation Enabling Technologies ($500.8 million, 47.8% gross margin, $114.5 million operating profit) and Medical Solutions ($479.8 million, 41.6% gross margin, $51.2 million operating profit).
- The medical market was approximately 53% of revenue and advanced industrial approximately 47%; the United States was 52.9% of revenue, and approximately 47% came from customers outside the U.S.
- Customer concentration is high: two medical OEMs represented approximately 12% and 11% of revenue, and the top ten customers approximately 42%.
- Strategy: raise the medical share of revenue (new products in minimally invasive and robotic surgery, ophthalmology, drug delivery, clinical lab), key account management and cross-selling to medical OEMs, medical technology acquisitions, and regionalize the manufacturing footprint into centers of excellence.
- The 2025 restructuring program (regionalized manufacturing, site closures) cost $14.0 million in 2025, with about $25.0 million expected in total by end-2026; operating cash flow fell to $64.1 million from $158.5 million on higher inventory.
- Balance sheet reloaded for M&A: $613.1 million net proceeds from 6.50% tangible equity units issued in November 2025, an $850.0 million revolver undrawn at year end, cash of $380.9 million; a $200.0 million buyback plan was approved in September 2025.
- About 3,000 employees (36% U.S., 55% Europe, 9% Asia), of which approximately 600 in engineering; backlog $481.2 million at 31 December 2025.

### [Novanta Inc. Form 10-Q for the third quarter of 2026 (quarter ended October 2, 2026)](https://www.sec.gov/Archives/edgar/data/1076930/000119312526453802/novt-20261002.htm)

Interim report · 2026-11-09

- Q3 2026 (quarter ended 2 October 2026) revenue was $305.0 million, +23.1%, of which the Riverpoint Medical acquisition added $32.9 million (13.3%); nine-month revenue $828.5 million, +14.7%.
- Automation Enabling Technologies revenue rose 16.0% to $145.4 million, with robotics and automation products +17.3% and precision manufacturing +13.7%; its gross margin reached 50.2% (47.3% a year earlier) and operating margin 28.1%.
- Medical Solutions revenue rose 30.3% to $159.7 million, but its gross margin fell to 39.9% (43.0%) and operating margin to 6.0% because of acquisition amortization and site-closure costs.
- Riverpoint Medical (minimally invasive surgical consumables) closed on 23 July 2026 for $1,200.6 million upfront, net of cash, plus a $250.0 million milestone payable by 8 January 2027.
- Funding: a $300 million private placement at $140.00 per share (June 2026), a $200.0 million delayed draw term loan and revolver borrowings; leverage ratio 2.43 against a 4.00 covenant.
- Q3 operating income fell 36.3% to $13.9 million and diluted EPS to $0.05, on $23.1 million of restructuring and acquisition costs and $14.7 million of intangible amortization.
- Nine-month operating cash flow jumped to $155.9 million from $55.3 million, helped by a customer supply-agreement payment and bonuses converted to equity.
- Supply risks named: AI-driven component shortages, Chinese export licences on rare-earth materials and magnets, tariffs, and the 2026 Iran conflict raising energy and freight costs.

### [Novanta Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/11/10/novanta-novt-q3-2026-earnings-call-transcript/)

Executive talk · Matthijs Glastra, Chair and Chief Executive Officer · 2026-11-10

- CEO Matthijs Glastra called Q3 2026 "a milestone quarter": revenue +23% to $305 million, organic growth of nearly 10% (best in more than three years), adjusted EBITDA +38% to $80 million at a record 26% margin, adjusted EPS +21% to $1.05.
- Bookings grew 29% (18% excluding Riverpoint Medical), book-to-bill 1.08, backlog $543 million; new product revenue +23% and vitality index about 27% of sales year to date.
- Direction: "more medical, more recurring, and less cyclical"; medical is 53% of revenue, approaching 60% for a full year with Riverpoint; recurring consumables are roughly 25% of revenue; embedded-software intelligent subsystems roughly 25% of revenue and about 75% of launches.
- Riverpoint Medical contributed about $33 million in the quarter, in line with plan; Medical Solutions now reports two business units, advanced surgical technologies (+12% organic) and precision medicine (-5%).
- AET grew 16% on semiconductor, robotics and advanced manufacturing (together roughly 40% of pro forma revenue); air bearing spindles are sold out for two years and the business should double by 2028.
- A production slowdown at the Stockport (U.K.) factory is a roughly 200 basis point gross margin headwind in Q4; restart expected in Q1 2027.
- 2026 guidance: revenue $1,135-1,140 million (about 7% organic), adjusted EBITDA $274-277 million, adjusted EPS $3.66-3.71, operating cash flow about $200 million; 2027 seen at more than 15% reported growth and more than 20% adjusted EBITDA growth.
- Priorities: organic growth, deleveraging after Riverpoint, and 18 factories by end of Q1 2027 (from 21); Julie Eaton, ex-Halma, hired as President of robotics and automation.

### [Novanta Q4 and full-year 2025 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/24/novanta-novt-q4-2025-earnings-call-transcript/)

Executive talk · Matthijs Glastra, Chair and Chief Executive Officer · 2026-02-24

- On the Q4 2025 call (24 February 2026), CEO Matthijs Glastra reported record quarterly revenue (+9% reported, +2% organic) and bookings up 25% with a 1.11 book-to-bill; every business had double-digit bookings growth for the first time since 2022.
- Full-year 2025 revenue reached $981 million; full-year bookings grew 14%; new product sales grew over 60% and the vitality index was 22%.
- Q4 margins and cash flow missed the November guidance because Novanta "prioritized customer deliveries over the pace of our regional manufacturing transfers"; costs were adjusted in January.
- Growth platforms (next-generation insufflation, robotic surgery, physical AI for warehouse automation and humanoids, intelligent laser beam steering) are "a $4 billion incremental market opportunity by 2030"; advanced surgery targets approximately $400 million in revenue by 2030.
- Air bearing spindles are "the only qualified supplier for drilling AI-driven GPU boards", growing at a strong double-digit rate.
- M&A: "the largest acquisition pipeline in my tenure as CEO", focused on medical technologies, medical consumables, bioprocessing and embedded software, with nearly $1.5 billion of capacity after raising more than $600 million.
- 2026 guidance: revenue about $1,030-1,050 million (4% to 6% organic), adjusted gross margin about 47%, adjusted EBITDA $245-250 million, adjusted EPS $3.50-3.65, operating cash flow $145-185 million.
- Medical consumables were 15% of 2025 sales and growing double digits; medical exposure has grown to close to 55% of revenue "up from 10%" under Glastra.

## Questions about Novanta Inc.

### What does Novanta do?

Novanta engineers components and sub-systems, such as laser beam steering, precision motion, robotic tooling, surgical insufflators, pumps and consumables, that medical, life science and advanced industrial OEMs integrate into their own systems.

### What is Novanta's revenue?

FY2025 revenue was $980.6 million, up 3.3%. Novanta guides to 2026 revenue of $1,135-1,140 million, including Riverpoint Medical.

### How many employees does Novanta have?

Novanta had about 3,000 employees at 31 December 2025, approximately 36% in the United States, 55% in Europe and 9% in Asia.

### Who leads Novanta?

Matthijs Glastra is Chair of the Board and CEO, Robert Buckley is CFO, and John Lesica and Chuck Ravetto are Co-Chief Operating Officers.

### What is Novanta's strategy?

Become more medical, more recurring and less cyclical through new products, medical acquisitions such as Riverpoint Medical, and a regionalized manufacturing footprint, while delevering in the near term.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
